PR Newswire·Nov 9, 2026, 11:36 AM ET

Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment

Health care stocks rose on Nov. 9, 2026, with the State Street Health Care Select Sector SPDR ETF up 0.88% to $186.42 & the S&P 500 up 1.70% to 7,501.96.
CMS 2027 projections indicate the weighted average Medicare Advantage premium will fall 16.5% to $12.00, while the average Part D premium will rise slightly to $36.
Medicare Open Enrollment is active from Oct. 15, 2026, through Dec. 7, 2026.
Four of five featured companies raised full-year guidance, while one received FDA accelerated approval for a new cancer therapy.
Johnson & Johnson received FDA accelerated approval for RYBREVANT FASPRO as a single agent for recurrent or metastatic head & neck squamous cell carcinoma.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.44 billion in Q3, raised 2026 revenue guidance to $13.15–$13.25 billion, & completed its Crinetics Pharmaceuticals acquisition.
Humana raised its FY 2026 Adjusted EPS guidance to at least $9.50, reported Q3 GAAP revenues of $41.155 billion, & noted significant growth in CenterWell & Medicaid memberships.
Edwards Lifesciences reported 10.5% sales growth to $1.72 billion, raised full-year constant currency sales guidance to approximately 11.5%, & noted FDA approval for the PASCAL Precision system.
McKesson reported fiscal 2027 Q2 consolidated revenues of $111.0 billion, raised Adjusted EPS guidance to $45.60–$46.40, & completed the acquisition of Precision Medicine Group.